We studied the profiles of all-cause and cardiovascular (CVS) mortality among users of different antihypertensive classes in a Chinese population. From electronic patient records, a cohort study was conducted among 18 338 patients who ever newly prescribed an a-blocker, thiazide diuretic, b-blocker, calcium channel blocker (CCB) or agents acting on the renin-angiotensin system (RAS) without drug discontinuation or switching in the public primary-care sector in a large Territory of Hong Kong during January 2004-June 2007. The odds ratios of mortality (all-cause and CVS) were evaluated according to the prescribed antihypertensive drug classes by Cox proportional hazards regression analyses. A total of 823 deaths (4.5%) were reported during the study period. The crude proportions of all-cause mortality were highest in a-blockers (6.2%) and CCB (5.7%), but lowest in b-blockers (2.8%). Compared with CCB, patients on thiazide diuretics were shown to have statistically significantly lower all-cause (adjusted hazard ratios (aHRs) 0.75, 95% CI 0.60, 0.93, P ¼ 0.010) and CVS mortality (aHR 0.40, 95% CI 0.21, 0.78, P ¼ 0.007), but the 95% CI of the odds ratios of the major drug classes overlapped. When each drug class was used as a reference group, or when patients with only uncomplicated hypertension were included, their respective 95% CI similarly overlapped. Antihypertensive drug classes were associated with statistically comparable odds of all-cause and CVS mortality. This finding from real-life clinical practice further supports the position statements from international guidelines, which recommend that the major antihypertensive drug classes are suitable for initiating pharmacotherapy for the management of hypertension.
Introduction
Hypertension is a global health challenge owing to its high and rapidly growing worldwide prevalence in Caucasian countries, 1, 2 and also in the AsiaPacific regions including China. [3] [4] [5] It remains generally poorly controlled 6, 7 and has been reported as the most common global risk factor for cardiovascular (CVS) morbidity and mortality, carrying a huge public health burden. 1, 3 Many international guidelines have advised that the major antihypertensive drug classes are all suitable as an initial pharmacotherapy for management of hypertension. [8] [9] [10] These position statements are supported by a large number of high-quality randomised controlled trials, which showed similar mortality rates among users of the major antihypertensive drug classes. [11] [12] [13] [14] [15] [16] [17] This finding is convincingly showed when the Blood Pressure Lowering Treatment Trialists Collaboration published their meta-analysis from 162 341 patients and reported no significant differences in total and CVS mortality among users of thiazide diuretics, b-blockers, calcium channel blockers (CCBs) and angiotensinconverting enzyme inhibitors (ACEIs). 18 However, some limitations of these trials have been raised, [19] [20] [21] including the need to select higherrisk patients and thus uncomplicated, younger and lower-risk patients were under-represented. 8 These therapeutic programmes have also been criticised of not representing real clinical practice. As highlighted by Williams, 22 trial design has been further complicated by the tightening of treatment thresholds, which means that they did not compare the individual drug classes but treatment regimens.
It is unknown, therefore, whether the mortality rates among users of the major antihypertensive classes were also comparable in 'real-life practice.' This is an important question to be addressed, as mortality effects are a crucial consideration when physicians and policy-makers recommend particular antihypertensive drugs. Larger-scale epidemiological studies could better inform the pharmacological effects of antihypertensive prescriptions without potential selection biases inherent in clinical trials.
This study compared all-cause and CVS mortality among the users of the major antihypertensive drug classes in a large Chinese population. We tested the hypothesis that antihypertensive drug classes were associated with similar mortality rates even in epidemiological studies, a recognised conclusion from randomised trials.
Materials and methods

Data source
The Clinical Data Analysis Reporting System of the Hospital Authority of Hong Kong consists of all patient records in public primary-care health sector. It captures patients' demographics, clinical information including diagnoses and prescription details in every out-patient consultation. One of the major functions of Clinical Data Analysis Reporting System is research. 23 It is the single portal of information entry for all physicians practicing in the public sector in Hong Kong, and is a comprehensive record which allows cross-referencing when patients visit a different clinic in the public health sector. In addition, it is the policy of all public clinics in Hong Kong to have their drug prescription details doubly checked by the pharmacist professionals. With respect to these good practices the database can be regarded valid and reliable. An earlier study on the validation of this database reported high-data completeness on patient demographics (100%) and drug prescription details (99.98%). 24 This study included populations residing in the New Territory East Cluster of Hong Kong, which has a population of B1.3 million.
Subjects
Patients X18 years who attended the public primary-care clinics in the New Territory East Cluster, Hong Kong for the first time during the study period of January 2004-June 2007 and were newly prescribed an antihypertensive agent during this period were included. Each patient was classified according to the antihypertensive drug class prescribed. These include a-blockers, b-blockers, thiazide diuretics, CCBs and drugs acting on the reninangiotensin system (RAS), namely ACEIs and angiotensin-receptor blockers (ARBs). The profiles of all-cause and CVS mortality were analyzed. The database consists of information on patient mortality and its causes recorded by the attending physician in the death certificates. Exclusion criteria included patients already prescribed antihypertensive drugs before the study period, those on polytherapy (defined as the prescription of more than one antihypertensive drug class) or combination therapy (defined as the prescription of at least one single pill consisting of more than one active ingredient), as well as patients who discontinued or switched their drug prescription during the study period. We evaluated the medication possession ratio for each patient, an accepted metric for the evaluation of compliance using retrospective data. 25 It is defined as the ratio of total days of medication supplied (not including the last prescription) to total days in a period of time. 25 Those with medication possession ratio o0.8, accounting for 15% of the eligible subjects using the above criteria, were considered drug non-compliant and excluded.
The study was approved by the New Territory East Cluster, Hospital Authority and the Survey and Behavioural Research Ethics Committee, the Chinese University of Hong Kong.
Outcomes and covariates
The proportions of patients having all-cause and disease-specific deaths were compared according with their antihypertensive drug groups. The two major outcome variables were all-cause mortality and deaths because of CVS or cerebrovascular diseases (CVS mortality). Independent predictors of these two outcomes were the antihypertensive drug class prescribed, although potential confounding factors included patients' age, sex, patients' requirement to pay as a proxy measure of socioeconomic status, 24 and the type of comorbidity (including uncomplicated hypertension) as indicated by the presence of International Classification of Primary Care (ICPC) codes for individual patients in the database. These were for diabetes or glucose intolerance (ICPC T90, T901); CVS or cerebrovascular diseases (CVS diseases) (ICPC K90, K91, K74, K76, K75, K77, K84, K99); chronic lung diseases (ICPC R79, R95, R96) and chronic renal diseases (ICPC U14, U88, Y85, U78, Y79).
Statistical analysis
A descriptive analysis was performed and the proportions of patients having each type of morbidity, disease-specific mortality and all-cause mortality were compared using w 2 tests of homogeneity. Student's t-tests were used to compare continuous variables. Disease-specific mortality was classified into the following groups: (1) cancer, (2) CVS or cerebrovascular diseases, (3) respiratory diseases and (4) others. Two separate Cox proportional hazards regression analyses were performed with all-cause mortality and CVS mortality, respectively, as outcome variables. All the above covariates were entered into the models. We used the statistical package for social sciences (SPSS) version 13.0 (SPSS Inc., Chicago, IL, USA) to evaluate the best-fit values for each of the hazard ratios.
As sensitivity analyses each antihypertensive drug class was consecutively used as a reference group by repeating the regression analyses for both mortality outcomes. In addition, we further analyzed the association between CVS and all-cause mortality, respectively, with the antihypertensive drug class by analyzing patients coded with ICPC K86 (uncomplicated hypertension) only. All P-values o0.05 were regarded as statistically significant.
Results
Patient characteristics
We included a total of 18 338 patients who fulfilled our eligibility criteria ( Table 1 ). The majority of them were prescribed CCB (36.2%) and b-blockers (26.3%), followed by thiazide diuretics (17.0%), RAS (10.8%) and a-blockers (9.6%). Patients receiving a-blockers and CCB were the eldest (mean age 68.2 and 66.2 years, respectively) and those prescribed b-blockers were the youngest (mean age 60.0 years). More women than men received thiazides or b-blockers although the majority of patients on ablockers were male. CCB and RAS had comparable proportions of both genders.
Most patients were fee-payers and had only one type of morbidity (inclusive of uncomplicated hypertension). The majority of morbidities other than hypertension included diabetes or impaired glucose intolerance (28.2%), CVS diseases (5.3%) and chronic lung diseases (8.1%).
Cancer was the most common cause of death in the b-blocker group (34.5%), whereas in other drug Factors associated with all-cause mortality A total of 823 deaths (4.5%) were reported during the study period. The factors associated with allcause mortality were shown in Table 2 . As expected, more advanced age was strongly associated with mortality. All-cause mortality was also higher in males, in those of low socioeconomic status (fee waivers), and in patients with at least two morbidities (more than one coded condition). Among patients having only one morbidity, CVS diseases (aOR 2.17, Po0.001) and chronic lung diseases (aOR 1.62, Po0.001) were significantly associated with higher odds of all-cause deaths when compared with patients with no comorbidity. Among the major antihypertensive drug classes, thiazide diuretics were found to have a significantly lower risk of all-cause deaths (HR 0.75, P ¼ 0.010) when compared with CCB. All other antihypertensive drug groups were comparable with CCB in terms of odds of all-cause mortality. However, the 95% CI of all the drug classes overlapped, and this finding remained when each drug class was used as the reference group in turn. In addition, the initial P-value among antihypertensive drug classes is not statistically significant (P ¼ 0.057).
Factors associated with CVS mortality
The higher risk associated with advanced age and the presence of more than one morbidity remained statistically significant with greater magnitudes when CVS mortality instead of all-cause mortality was examined (Table 3 ). The hazard ratios of each antihypertensive drug classes overlapped regardless of which antihypertensive drug class was used as the reference group, and the initial P-value among antihypertensive drug classes is marginally significant (P ¼ 0.050).
Repeat regression analysis of all-cause and CVS mortality including patients coded with ICPC K86 only (that is, patients with uncomplicated hypertension and no comorbidities) showed statistically similar odds of antihypertensive drug classes with respect to all-cause mortality and CVS mortality when compared with RAS. Again, repeated analysis with each antihypertensive drug class as the reference group reported overlapping 95% CI of the adjusted hazard ratios among all drug classes (results not shown). Comorbidity is defined as disease conditions other than uncomplicated hypertension in any one of the following categories: DM/IGT, CVD, lung diseases and renal diseases.
Discussion
Major findings
This study has found that in patients of Chinese ethnicity attending primary health care within the public health care system of Hong Kong, a similar likelihood of all-cause and CVS mortality was associated with prescription of the major antihypertensive drug classes. These odds remained statistically similar when each drug class was used a reference group, or when only patients coded with uncomplicated hypertension were analyzed. Thus, we are confident that this is a robust finding.
Interpretation and relationship with published literatures
Our findings suggest that in real-life clinical settings users of the major antihypertensive drug classes were similarly associated with all-cause and CVS mortality. This lends further evidence support to randomised controlled trials involving head-to-head comparison of the major antihypertensive drug classes that reported comparable mortality outcomes across classes. Important landmark trials, notably ALLHAT, 11 ANBP2, 12 INSIGHT, 13 HAPPHY, 14 
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These findings were also compatible with a meta-analysis of randomised controlled trials showing no clear difference between the effects of the drug classes on major CVS events. 27 However, to our knowledge there have been no large-scale published observational studies on comparison among various groups of antihypertensive drugs using mortality as an outcome in Chinese patients.
The similarity between the findings from this study and the landmark trials implies the robustness of conclusions drawn by randomised trials, despite possible controversies on their limitations. [19] [20] [21] [22] In addition, our participants were all Chinese patients, whereas the major trials have focused on Caucasian subjects or mixed ethnic groups. Ethnicity plays an important role in the pharmacological actions of antihypertensive drugs. 28 It is well documented that black races responds better to diuretics than non-blacks 29 presumably because of lower-rennin status, 30 hence further research is required with other races. 
Strengths and weaknesses of this study
The large sample size and completeness of the clinical database in this study allowed for a statistically robust regression analyses on the mortality outcomes associated with the major classes of antihypertensive agents. In contrast to clinical trials, this study represents a true reflection of association between antihypertensive drug classes and mortality in a large population. However, several limitations existed. First, the sampling frame was from one single Territory of Hong Kong (out of a total of seven) although we feel this is unlikely to influence the outcomes found. Similar patterns of prescribing to those found in this study have been reported in earlier smaller studies in other clusters of Hong Kong. [31] [32] [33] Hypertension is the second commonest condition seen in primary care clinics in the public health-care sector, 33 and the majority of the local population is under the public health services for management of hypertension. 34 In addition, hypertensive patients on different classes of antihypertensive drugs had different demographic and clinical characteristics. It is noted that heterogeneity owing to indication bias includes the younger age and lesser number of morbidities among b-blocker users, and higher proportions of diabetes/impaired glucose tolerance, CVS diseases and chronic renal diseases among RAS users. In addition, we have no data on blood pressure readings, the severity of morbidities and other concomitant CVS risk factors such as smoking and obesity, which should make interpretation more cautious.
Implications for policy and practice
This study suggest that all major antihypertensive drug classes are suitable choice of first-line therapy for hypertension in Chinese patients in terms of mortality outcomes, which is an important finding to inform policy-makers to implement clinical guidelines and could potentially affect physician choice of antihypertensive prescriptions. The favourable efficacy profiles and affordability of thiazides make them a good choice from an economic perspective also. [35] [36] [37] Our earlier epidemiological studies showed that the major antihypertensive drug classes were also similar in their cumulative incidences of drug discontinuation and switching, 38 ,39 dyslipidemia, 40 hyponatremia, 41 hypokalemia 41 and hyperglycaemia. 42 This is compatible to recommendations from the findings of this study. Antihypertensive prescribing in the substantial private sector, for instance in Hong Kong, is a bigger challenge, as it is unregulated, has no compulsory quality assurance systems in place, and operates on a fee-for-service basis with doctors' income being directly related to profit margins from consultation fees and drug charges.
In addition, our finding that more than 15% of patients were non-compliant to antihypertensive drugs (medication possession ratio o0.8) highlights an important clinical issue, and requires further studies to compare drug compliance according to antihypertensive drug classes.
This study showed that no antihypertensive drug class was significantly inferior to other agents in terms of association with mortality outcomes, in line with the findings from randomised controlled trials. Combined together, we suggest that major antihypertensive drug classes are equally suitable for the initiation of antihypertensive treatment, in which evidence is now derived from large population realworld practice.
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